Floatz logo

Lorigerlimab

Regorafenib

M.D. Anderson Cancer Centermonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the Regorafenib cohort.

Asset / SponsorPhaseRating
Regorafenib
M.D. Anderson Cancer Center
Phase 3BB
Irinotecan
Sun Yat-sen University
Phase 3B
Raltitrexed
China Medical University, China
Phase 1/2CC
Tuvonralimab
JIANG LONGWEI
Early Phase 1C
Iparomlimab
JIANG LONGWEI
Early Phase 1C

View all 9 →

Same molecule, other indications

Lorigerlimab is also rated in:

castration-resistant prostate carcinomaDormant
BB
Indicative ·
64 / 100
View asset →
prostate cancerDormant
B
Indicative ·
57 / 100
View asset →
Immune Checkpoint InhibitorDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →